請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/98909完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 曾宇鳳 | zh_TW |
| dc.contributor.advisor | Yufeng Jane Tseng | en |
| dc.contributor.author | 林首志 | zh_TW |
| dc.contributor.author | Shou-Zhi Lin | en |
| dc.date.accessioned | 2025-08-20T16:14:55Z | - |
| dc.date.available | 2025-08-21 | - |
| dc.date.copyright | 2025-08-20 | - |
| dc.date.issued | 2025 | - |
| dc.date.submitted | 2025-08-05 | - |
| dc.identifier.citation | [1] H. Sung et al., “Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA A Cancer J Clinicians, vol. 71, no. 3, pp. 209–249, May 2021, doi: 10.3322/caac.21660.
[2] C. Allemani et al., “Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries,” The Lancet, vol. 391, no. 10125, pp. 1023–1075, Mar. 2018, doi: 10.1016/S0140-6736(17)33326-3. [3] P. Goldstraw et al., “The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer,” Journal of Thoracic Oncology, vol. 11, no. 1, pp. 39–51, Jan. 2016, doi: 10.1016/j.jtho.2015.09.009. [4] S. Blandin Knight, P. A. Crosbie, H. Balata, J. Chudziak, T. Hussell, and C. Dive, “Progress and prospects of early detection in lung cancer,” Open Biol., vol. 7, no. 9, p. 170070, Sep. 2017, doi: 10.1098/rsob.170070. [5] L. M. Seijo et al., “Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges,” Journal of Thoracic Oncology, vol. 14, no. 3, pp. 343–357, Mar. 2019, doi: 10.1016/j.jtho.2018.11.023. [6] M. M. Oken et al., “Screening by Chest Radiograph and Lung Cancer Mortality: The Prostate, Lung, Colorectal, and Ovarian (PLCO) Randomized Trial,” JAMA, vol. 306, no. 17, p. 1865, Nov. 2011, doi: 10.1001/jama.2011.1591. [7] H. J. De Koning et al., “Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial,” N Engl J Med, vol. 382, no. 6, pp. 503–513, Feb. 2020, doi: 10.1056/NEJMoa1911793. [8] S. J. Adams, E. Stone, D. R. Baldwin, R. Vliegenthart, P. Lee, and F. J. Fintelmann, “Lung cancer screening,” The Lancet, vol. 401, no. 10374, pp. 390–408, Feb. 2023, doi: 10.1016/S0140-6736(22)01694-4. [9] C. Freitas et al., “The Role of Liquid Biopsy in Early Diagnosis of Lung Cancer,” Front. Oncol., vol. 11, p. 634316, Apr. 2021, doi: 10.3389/fonc.2021.634316. [10] W. Li et al., “Liquid biopsy in lung cancer: significance in diagnostics, prediction, and treatment monitoring,” Mol Cancer, vol. 21, no. 1, p. 25, Dec. 2022, doi: 10.1186/s12943-022-01505-z. [11] A. Krilaviciute, J. A. Heiss, M. Leja, J. Kupcinskas, H. Haick, and H. Brenner, “Detection of cancer through exhaled breath: a systematic review,” Oncotarget, vol. 6, no. 36, pp. 38643–38657, Nov. 2015, doi: 10.18632/oncotarget.5938. [12] W. Ibrahim et al., “Breathomics for the clinician: the use of volatile organic compounds in respiratory diseases,” Thorax, vol. 76, no. 5, pp. 514–521, May 2021, doi: 10.1136/thoraxjnl-2020-215667. [13] P. Wang et al., “Identification of lung cancer breath biomarkers based on perioperative breathomics testing: A prospective observational study,” eClinicalMedicine, vol. 47, p. 101384, May 2022, doi: 10.1016/j.eclinm.2022.101384. [14] Y. Saalberg and M. Wolff, “VOC breath biomarkers in lung cancer,” Clinica Chimica Acta, vol. 459, pp. 5–9, Aug. 2016, doi: 10.1016/j.cca.2016.05.013. [15] M. McCulloch, T. Jezierski, M. Broffman, A. Hubbard, K. Turner, and T. Janecki, “Diagnostic Accuracy of Canine Scent Detection in Early- and Late-Stage Lung and Breast Cancers,” Integr Cancer Ther, vol. 5, no. 1, pp. 30–39, Mar. 2006, doi: 10.1177/1534735405285096. [16] R. Ehmann et al., “Canine scent detection in the diagnosis of lung cancer: revisiting a puzzling phenomenon,” European Respiratory Journal, vol. 39, no. 3, pp. 669–676, Mar. 2012, doi: 10.1183/09031936.00051711. [17] N. Peled et al., “Non-invasive Breath Analysis of Pulmonary Nodules,” Journal of Thoracic Oncology, vol. 7, no. 10, pp. 1528–1533, Oct. 2012, doi: 10.1097/JTO.0b013e3182637d5f. [18] H. Lemjabbar-Alaoui, O. U. Hassan, Y.-W. Yang, and P. Buchanan, “Lung cancer: Biology and treatment options,” Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, vol. 1856, no. 2, pp. 189–210, Dec. 2015, doi: 10.1016/j.bbcan.2015.08.002. [19] Y. Zhang et al., “Global variations in lung cancer incidence by histological subtype in 2020: a population-based study,” The Lancet Oncology, vol. 24, no. 11, pp. 1206–1218, Nov. 2023, doi: 10.1016/S1470-2045(23)00444-8. [20] P. J. Mazzone et al., “Exhaled Breath Analysis with a Colorimetric Sensor Array for the Identification and Characterization of Lung Cancer,” Journal of Thoracic Oncology, vol. 7, no. 1, pp. 137–142, Jan. 2012, doi: 10.1097/JTO.0b013e318233d80f. [21] C. Wang et al., “Exploratory study on classification of lung cancer subtypes through a combined K-nearest neighbor classifier in breathomics,” Sci Rep, vol. 10, no. 1, p. 5880, Apr. 2020, doi: 10.1038/s41598-020-62803-4. [22] R. Schmid et al., “Integrative analysis of multimodal mass spectrometry data in MZmine 3,” Nat Biotechnol, vol. 41, no. 4, pp. 447–449, Apr. 2023, doi: 10.1038/s41587-023-01690-2. [23] A. Smirnov, Y. Qiu, W. Jia, D. I. Walker, D. P. Jones, and X. Du, “ADAP-GC 4.0: Application of Clustering-Assisted Multivariate Curve Resolution to Spectral Deconvolution of Gas Chromatography–Mass Spectrometry Metabolomics Data,” Anal. Chem., vol. 91, no. 14, pp. 9069–9077, Jul. 2019, doi: 10.1021/acs.analchem.9b01424. [24] S. E. Stein and D. R. Scott, “Optimization and testing of mass spectral library search algorithms for compound identification,” J. Am. Soc. Mass Spectrom., vol. 5, no. 9, pp. 859–866, Sep. 1994, doi: 10.1016/1044-0305(94)87009-8. [25] S. R. Searle, F. M. Speed, and G. A. Milliken, “Population Marginal Means in the Linear Model: An Alternative to Least Squares Means,” The American Statistician, vol. 34, no. 4, pp. 216–221, Nov. 1980, doi: 10.1080/00031305.1980.10483031. [26] Y. Benjamini and Y. Hochberg, “Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing,” Journal of the Royal Statistical Society: Series B (Methodological), vol. 57, no. 1, pp. 289–300, Jan. 1995, doi: 10.1111/j.2517-6161.1995.tb02031.x. [27] H. Scheffe, “A Method for Judging all Contrasts in the Analysis of Variance,” Biometrika, vol. 40, no. 1/2, p. 87, Jun. 1953, doi: 10.2307/2333100. [28] R Core Team, R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, 2023. [Online]. Available: https://www.R-project.org/ [29] A. Kassambara, rstatix: Pipe-Friendly Framework for Basic Statistical Tests. 2023. [Online]. Available: https://CRAN.R-project.org/package=rstatix [30] R. V. Lenth, emmeans: Estimated Marginal Means, aka Least-Squares Means. 2023. [Online]. Available: https://CRAN.R-project.org/package=emmeans [31] W. N. Venables and B. D. Ripley, Modern Applied Statistics with S, Fourth. New York: Springer, 2002. [Online]. Available: https://www.stats.ox.ac.uk/pub/MASS4/ [32] Z. Pang et al., “MetaboAnalyst 6.0: towards a unified platform for metabolomics data processing, analysis and interpretation,” Nucleic Acids Research, p. gkae253, Apr. 2024, doi: 10.1093/nar/gkae253. [33] F. Schmidt et al., “Mapping the landscape of lung cancer breath analysis: A scoping review (ELCABA),” Lung Cancer, vol. 175, pp. 131–140, Jan. 2023, doi: 10.1016/j.lungcan.2022.12.003. [34] I. A. Ratiu, T. Ligor, V. Bocos-Bintintan, C. A. Mayhew, and B. Buszewski, “Volatile Organic Compounds in Exhaled Breath as Fingerprints of Lung Cancer, Asthma and COPD,” JCM, vol. 10, no. 1, p. 32, Dec. 2020, doi: 10.3390/jcm10010032. [35] S. Janfaza, B. Khorsand, M. Nikkhah, and J. Zahiri, “Digging deeper into volatile organic compounds associated with cancer,” Biology Methods and Protocols, vol. 4, no. 1, p. bpz014, Jan. 2019, doi: 10.1093/biomethods/bpz014. [36] M. Hakim et al., “Volatile Organic Compounds of Lung Cancer and Possible Biochemical Pathways,” Chem. Rev., vol. 112, no. 11, pp. 5949–5966, Nov. 2012, doi: 10.1021/cr300174a. [37] D. Zimmermann, M. Hartmann, M. P. Moyer, J. Nolte, and J. I. Baumbach, “Determination of volatile products of human colon cell line metabolism by GC/MS analysis,” Metabolomics, vol. 3, no. 1, pp. 13–17, Mar. 2007, doi: 10.1007/s11306-006-0038-y. [38] International Agency for Research on Cancer, Ed., Re-evaluation of some organic chemicals, hydrazine and hydrogen peroxide: this publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 17 - 24 February 1998. in IARC monographs on the evaluation of carcinogenic risks to humans, no. 71. Lyon: IARC, 1999. [39] H. Warden, H. Richardson, L. Richardson, J. Siemiatycki, and V. Ho, “Associations between occupational exposure to benzene, toluene and xylene and risk of lung cancer in Montréal,” Occup Environ Med, vol. 75, no. 10, pp. 696–702, Oct. 2018, doi: 10.1136/oemed-2017-104987. [40] Z. Khorrami et al., “Multiple air pollutant exposure and lung cancer in Tehran, Iran,” Sci Rep, vol. 11, no. 1, p. 9239, Apr. 2021, doi: 10.1038/s41598-021-88643-4. [41] International Agency for Research on Cancer, Ed., Some chemicals that cause tumours of the kidney or urinary bladder in rodents and some other substances: this publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 13 - 20 October 1998. in IARC monographs on the evaluation of carcinogenic risks to humans, no. 73. Lyon: IARC, 1999. [42] Centre international de recherche sur le cancer, Ed., Some chemicals present in industrial and consumer products, food and drinking-water. in IARC monographs on the evaluation of carcinogenic risks to humans, no. 101. Lyon: International agency for research on cancer, 2013. [43] Some chemicals used as solvents and in polymer manufacture. Lyon, France: International Agency for Research on Cancer, World Health Organization, 2017. [44] International Agency for Research on Cancer, Ed., Formaldehyde, 2-Butoxyethanol and 1-tert-Butoxypropan-2-ol: this publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 2 - 9 June 2004. in IARC monographs on the evaluation of carcinogenic risks to humans, no. 88. Lyon: IARC, 2006. [45] C. Wang et al., “Exhaled volatile organic compounds as lung cancer biomarkers during one-lung ventilation,” Sci Rep, vol. 4, no. 1, p. 7312, Dec. 2014, doi: 10.1038/srep07312. [46] J. M. Sanders, J. R. Bucher, J. C. Peckham, G. E. Kissling, M. R. Hejtmancik, and R. S. Chhabra, “Carcinogenesis studies of cresols in rats and mice,” Toxicology, vol. 257, no. 1–2, pp. 33–39, Mar. 2009, doi: 10.1016/j.tox.2008.12.005. [47] A. Peralbo-Molina, M. Calderón-Santiago, F. Priego-Capote, B. Jurado-Gámez, and M. D. Luque De Castro, “Identification of metabolomics panels for potential lung cancer screening by analysis of exhaled breath condensate,” J. Breath Res., vol. 10, no. 2, p. 026002, Mar. 2016, doi: 10.1088/1752-7155/10/2/026002. [48] A. Sales, L. D. O. Felipe, and J. L. Bicas, “Production, Properties, and Applications of α-Terpineol,” Food Bioprocess Technol, vol. 13, no. 8, pp. 1261–1279, Aug. 2020, doi: 10.1007/s11947-020-02461-6. [49] M. K. Ediriweera, N. B. To, Y. Lim, and S. K. Cho, “Odd-chain fatty acids as novel histone deacetylase 6 (HDAC6) inhibitors,” Biochimie, vol. 186, pp. 147–156, Jul. 2021, doi: 10.1016/j.biochi.2021.04.011. [50] G. Pascual et al., “Dietary palmitic acid promotes a prometastatic memory via Schwann cells,” Nature, vol. 599, no. 7885, pp. 485–490, Nov. 2021, doi: 10.1038/s41586-021-04075-0. [51] X. Zhang et al., “Palmitic Acid Promotes Lung Metastasis of Melanomas via the TLR4/TRIF-Peli1-pNF-κB Pathway,” Metabolites, vol. 12, no. 11, p. 1132, Nov. 2022, doi: 10.3390/metabo12111132. [52] X. Wang, C. Zhang, and N. Bao, “Molecular mechanism of palmitic acid and its derivatives in tumor progression,” Front. Oncol., vol. 13, p. 1224125, Aug. 2023, doi: 10.3389/fonc.2023.1224125. [53] S. Miyamoto et al., “Systemic Metabolomic Changes in Blood Samples of Lung Cancer Patients Identified by Gas Chromatography Time-of-Flight Mass Spectrometry,” Metabolites, vol. 5, no. 2, pp. 192–210, Apr. 2015, doi: 10.3390/metabo5020192. [54] S. Qi et al., “High-resolution metabolomic biomarkers for lung cancer diagnosis and prognosis,” Sci Rep, vol. 11, no. 1, p. 11805, Jun. 2021, doi: 10.1038/s41598-021-91276-2. [55] P. Kubáň and F. Foret, “Exhaled breath condensate: Determination of non-volatile compounds and their potential for clinical diagnosis and monitoring. A review,” Analytica Chimica Acta, vol. 805, pp. 1–18, Dec. 2013, doi: 10.1016/j.aca.2013.07.049. | - |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/98909 | - |
| dc.description.abstract | 肺癌的早期偵測可以大幅改善病人的治療結果。當前肺癌篩檢的主要方法是低劑量電腦斷層掃描，但仍有開發更快速且更具成本效益的篩檢方法的需求。本研究探討了呼出氣體中揮發性有機化合物的代謝體學分析作為肺癌早期偵測工具的潛力。
我們使用頂空固相微萃取法和氣相層析質譜法，分析了72名肺癌患者和13名健康個體呼出氣體凝結液樣本中揮發性有機化合物的組成。透過單變量以及多變量分析，我們發現肺癌患者與健康個體之間揮發性有機化合物的組成有顯著差異，而肺癌不同分期及兩種肺癌亞型（腺癌和鱗狀細胞癌）之間的差異則不顯著，我們提出了18種有潛力作為肺癌診斷生物標記的揮發性有機化合物和5種有潛力作為肺癌分期生物標記的揮發性有機化合物。然而，仍需進一步的研究來驗證這些潛在生物標記的可靠性。 | zh_TW |
| dc.description.abstract | Early detection of lung cancer can significantly improve patient outcomes. Low-dose computed tomography (LDCT) is the main lung cancer screening method, yet developing other quicker and more cost-effective methods is desirable. This study investigated the potential of breathomic analysis of volatile organic compounds (VOCs) in exhaled breath as a tool for the early detection of lung cancer.
We analyzed the VOC composition in exhaled breath condensate (EBC) samples collected from 72 lung cancer patients and 13 healthy individuals using headspace solid-phase microextraction (HS-SPME) and gas chromatography–mass spectrometry (GC–MS). By univariate and multivariate analysis, we found significant differences in VOC profiles between lung cancer patients and healthy individuals. In contrast, the differences between lung cancer stages and the two lung cancer subtypes, adenocarcinoma (AC) and squamous cell carcinoma (SCC), were nonsignificant. We proposed 18 VOCs as potential biomarkers for lung cancer diagnosis and 5 for cancer staging. However, additional studies are required to validate these potential biomarkers. | en |
| dc.description.provenance | Submitted by admin ntu (admin@lib.ntu.edu.tw) on 2025-08-20T16:14:55Z No. of bitstreams: 0 | en |
| dc.description.provenance | Made available in DSpace on 2025-08-20T16:14:55Z (GMT). No. of bitstreams: 0 | en |
| dc.description.tableofcontents | 誌謝 i
中文摘要 ii Abstract iii Contents iv List of Figures vi List of Tables vii Glossary viii Chapter 1 Introduction 1 Chapter 2 Materials and Methods 4 2.1 Study Subjects 4 2.2 EBC Sample Collection 4 2.3 HS-SPME Sampling 4 2.4 GC–TOF-MS Analysis 5 2.5 Compound Identification 6 2.6 Statistical Analysis 8 Chapter 3 Results and Discussion 9 3.1 Overview of the Data 9 3.2 Univariate Analysis of the VOC Profiles 13 3.2.1 ANCOVA Identified Some VOCs That Have Different Levels among Control Subjects, Patients with Adenocarcinoma, and Patients with Squamous Cell Carcinoma 13 3.2.2 ANCOVA Identified Some VOCs That Have Different Levels between Lung Cancer Stages 15 3.3 Multivariate Analysis of the VOC Profiles 18 3.3.1 PCA and PLS-DA Could Discriminate between VOC Profiles in Lung Cancer Patients and Control Subjects 18 3.3.2 PLS-DA Failed to Discriminate between VOC Profiles in Patients with AC and Patients with SCC 21 3.3.3 PLS-DA Failed to Discriminate between VOC Profiles in Patients with Different Cancer Stages 23 3.4 Potential VOC Biomarkers of Lung Cancer 24 3.5 Limitations 29 Chapter 4 Conclusion 31 References 32 | - |
| dc.language.iso | en | - |
| dc.subject | 呼吸代謝體學 | zh_TW |
| dc.subject | 生物標記 | zh_TW |
| dc.subject | 肺癌偵測 | zh_TW |
| dc.subject | 揮發性有機化合物 | zh_TW |
| dc.subject | 代謝體學 | zh_TW |
| dc.subject | 呼氣分析 | zh_TW |
| dc.subject | 呼出氣體凝結液 | zh_TW |
| dc.subject | volatile organic compounds | en |
| dc.subject | biomarkers | en |
| dc.subject | exhaled breath condensate | en |
| dc.subject | metabolomics | en |
| dc.subject | breath analysis | en |
| dc.subject | breathomics | en |
| dc.subject | lung cancer detection | en |
| dc.title | 肺癌患者呼出氣體凝結液的呼吸體學分析 | zh_TW |
| dc.title | Breathomics Analysis of the Exhaled Breath Condensate of Lung Cancer Patients | en |
| dc.type | Thesis | - |
| dc.date.schoolyear | 113-2 | - |
| dc.description.degree | 碩士 | - |
| dc.contributor.oralexamcommittee | 郭天爵;王三源;何肇基 | zh_TW |
| dc.contributor.oralexamcommittee | Tien-Chueh Kuo;San-Yuan Wang;Chao-Chi Ho | en |
| dc.subject.keyword | 肺癌偵測,呼吸代謝體學,呼氣分析,代謝體學,揮發性有機化合物,呼出氣體凝結液,生物標記, | zh_TW |
| dc.subject.keyword | lung cancer detection,breathomics,breath analysis,metabolomics,volatile organic compounds,exhaled breath condensate,biomarkers, | en |
| dc.relation.page | 35 | - |
| dc.identifier.doi | 10.6342/NTU202504043 | - |
| dc.rights.note | 同意授權(全球公開) | - |
| dc.date.accepted | 2025-08-11 | - |
| dc.contributor.author-college | 電機資訊學院 | - |
| dc.contributor.author-dept | 資訊工程學系 | - |
| dc.date.embargo-lift | 2025-08-21 | - |
| 顯示於系所單位： | 資訊工程學系 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-113-2.pdf | 944.87 kB | Adobe PDF | 檢視/開啟 |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。